Equities analysts forecast that Mateon Therapeutics Inc (NASDAQ:MATN) will report earnings per share of ($0.11) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Mateon Therapeutics’ earnings. Mateon Therapeutics reported earnings per share of ($0.12) during the same quarter last year, which suggests a positive year-over-year growth rate of 8.3%. The business is expected to issue its next quarterly earnings results on Monday, November 13th.

On average, analysts expect that Mateon Therapeutics will report full year earnings of ($0.42) per share for the current financial year. For the next year, analysts expect that the company will post earnings of ($0.50) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Mateon Therapeutics.

Mateon Therapeutics (NASDAQ:MATN) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.03.

Several equities analysts have recently issued reports on the company. Maxim Group reaffirmed a “hold” rating on shares of Mateon Therapeutics in a report on Tuesday, August 1st. Zacks Investment Research lowered Mateon Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, May 13th. Finally, Roth Capital assumed coverage on Mateon Therapeutics in a report on Thursday, April 20th. They issued a “buy” rating and a $2.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Mateon Therapeutics presently has an average rating of “Buy” and a consensus target price of $2.00.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.dailypolitical.com/2017/08/06/mateon-therapeutics-inc-matn-expected-to-post-earnings-of-0-11-per-share.html.

Shares of Mateon Therapeutics (NASDAQ:MATN) traded down 5.76% on Friday, hitting $0.35. The stock had a trading volume of 17,100 shares. The company’s market capitalization is $9.29 million. The company has a 50-day moving average of $0.35 and a 200 day moving average of $0.53. Mateon Therapeutics has a 52 week low of $0.27 and a 52 week high of $0.89.

Mateon Therapeutics Company Profile

Mateon Therapeutics, Inc, formerly OXiGENE, Inc, is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT.

Get a free copy of the Zacks research report on Mateon Therapeutics (MATN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mateon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.